📊Fast4ward Learning poll results are in! How will VERONA impact treatment of higher-risk MDS? 🔹 67% will wait for subgroup analysis 🔹 33% to use Aza/Ven more selectively 📣 Subgroup data coming at #ASH25 (Sat, Dec 6 PM) #MDS #VERONA #Hematology #Fast4wardLearning
Certain MDS subtypes may signal higher TP53 mutation risk. 📌 TP53 mutations are more common in MDS with excess blasts and ring sideroblasts—especially poor-risk profiles (eg, del(5q)/−5q, SF3B1–wild type). 🔍 TP53 wild-type is more frequent in normal karyotype MDS. Has this…
PV Disease Evolution: Tracking WBC trends, molecular burden, and symptoms is crucial to identifying loss of disease control. 🩸What indicators do you find most predictive of progression, and when do you reassess the need for cytoreduction or JAK inhibition? #PolycythemiaVera #MPN…
In recent Fast4ward Learning AML programs: 📊 88% of academic physicians reported NGS turnaround ≤7 days ⏱ Community physicians more often waited 8–21 days Delays can force empirical treatment instead of mutation-directed therapy. 👉 How can we ensure timely, actionable testing…
How does differentiation syndrome (DS) most commonly present in real-world practice? From a recent Fast4ward Learning APP program: 🔹 Dyspnea – 25.8% (most frequent) 🔹 Pulmonary infiltrates/pleural effusions – 22.6% 🔹 Weight gain/edema – 22.6% 🔹 Fever – 19.4% Respiratory +…
Are there early cytogenetic clues to TP53 mutations in MDS/AML? 📌 72% occur in complex karyotypes involving chr5 👉 ~19% seen even with isolated del(5q) 🧬 Strongly linked to chr7/17 co-aberrations (73–100%) Do cytogenetic patterns influence your suspicion before NGS results?…
Shifting the AML Treatment Paradigm: FDA Approves Ziftomenib The treatment landscape in AML continues to evolve — how will this latest approval shape your approach to managing R/R NPM1-mutated disease? The U.S. FDA has granted full approval of KOMZIFTI™ (ziftomenib) for adult…
PV treatment is evolving. 📕 2025 NCCN now lists Besremi® as a preferred first-line option for all PV risk groups. 🔬 Data show markedly longer time in molecular response (66.7% vs 8.4%). ❓ Is disease modification shaping your PV therapy choices?
United States Trends
- 1. #StrangerThings5 161K posts
- 2. Thanksgiving 635K posts
- 3. Reed Sheppard 3,614 posts
- 4. Afghan 257K posts
- 5. Podz 3,283 posts
- 6. robin 72.4K posts
- 7. BYERS 31.8K posts
- 8. holly 52.7K posts
- 9. National Guard 630K posts
- 10. Gonzaga 8,060 posts
- 11. Dustin 85K posts
- 12. #AEWDynamite 21.1K posts
- 13. Amen Thompson 1,433 posts
- 14. Michigan 76.9K posts
- 15. Tini 8,189 posts
- 16. Erica 13.6K posts
- 17. Rahmanullah Lakanwal 97.4K posts
- 18. Will Richard 2,080 posts
- 19. #Survivor49 3,042 posts
- 20. Jardine 6,556 posts
Something went wrong.
Something went wrong.